http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
Appaloosa's 13F Shows New Stakes in Altria (MO), AT&T Inc (T), Disney (DIS), PayPal (PYPL) (More...)
View Older Stories
-
AbbVie (ABBV) Completes Acquisition of Allergan (AGN)
-
AbbVie (ABBV), Allergan (AGN) Merger Cleared by FTC
-
AbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie's Acquisition of Allergan
-
AbbVie (ABBV), Allergan (AGN) Sign Consent Decree Agreement with FTC Staff on Pending Transaction
-
AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction
-
AbbVie (ABBV), Allergan Receive Final European Approval to Close Pending Transaction
-
AbbVie and Allergan Receive Final European Approval to Close Pending Transaction
-
AbbVie (ABBV), Allergan (AGN) Report Agreements to Divest Brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase)
-
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
-
Ironwood Pharma (IRWD), Allergan (AGN) Settle LINZESS (linaclotide) Patent Litigation with Teva (TEVA)
-
Ironwood and Allergan Announce Settlement with Teva Resolving LINZESS® (linaclotide) Patent Litigation
-
Ironwood Pharma (IRWD), Allergan (AGN) Announce Settlement Resolving LINZESS Patent Litigation
-
Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation
-
Amgen (AMGN), Allergan (AGN) Submit BLA For ABP 798, Biosimilar Candidate To Rituxan, to FDA
-
Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration
-
AbbVie (ABBV) and Allergan (AGN) Receive Second Request from FTC on Pending Transaction
-
AbbVie and Allergan Receive Second Request from Federal Trade Commission on Pending Transaction
-
Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman
-
Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)
-
Amgen (AMGN), Allergan (AGN) Report FDA Approval for MVASI (bevacizumab-awwb) and KANJINTI (trastuzumab-anns); Announce U.S. Availability
-
Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States
-
AbbVie (ABBV) Announces Agreement to Acquire Allergan (AGN) in $63 Billion Deal
-
AbbVie to Acquire Allergan in Transformative Move for Both Companies
-
Ironwood Pharma (IRWD), Allergan (AGN) Announce Positive Topline Data from Phase IIIb Trial of LINZESS (linaclotide) in Adults with IBS-C
-
Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
-
FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
-
Ironwood Pharma (IRWD), Allergen (AGN) Commence Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D
-
CoolSculpting® and Sonja Morgan Talk Bikini Denial Just In Time For Summer
-
CoolSculpting® and Sonja Morgan Partner to Talk Bikini Denial
-
Amgen (AMGN), Allergan (AGN) Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
-
Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
-
CoolSculpting® and Sonja Morgan Partner To Get Real About Self-Care
-
Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation
-
Aegon UK extends partnership with Atos for administration services
-
Aegon UK extends partnership with Atos for administration services
-
CoolSculpting® And Kristin Davis Partner To Overcome Denim Denial Blues
-
Allergan (AGN) Receives FDA Clearance to Treat Area Below The Jawline With CoolSculpting
-
Allergan Receives FDA Clearance To Treat Area Below The Jawline With CoolSculpting®
-
Aegon’s US capital position to benefit significantly from merger of legal entities
-
Aegon’s US capital position to benefit significantly from merger of legal entities
-
Aegon announces purchase of shares to neutralize 2018 interim stock dividend
-
Aegon announces purchase of shares to neutralize 2018 interim stock dividend
-
Aegon announces purchase of shares to neutralize 2018 interim stock dividend
-
Aegon announces purchase of shares to neutralize 2018 interim stock dividend
-
US subsidiaries Aegon reach settlement with SEC
-
US subsidiaries Aegon reach settlement with SEC
-
Aegon reports strong first half 2018 results
-
Aegon reports strong first half 2018 results
-
Aegon to divest its businesses in Czech Republic and Slovakia
-
Aegon to divest its businesses in Czech Republic and Slovakia

